## PROGRAM AT A GLANCE

### TIME | SUNDAY 5 SEPT | MONDAY 6 SEPT | TUESDAY 7 SEPT | WEDNESDAY 8 SEPT
--- | --- | --- | --- | ---
**AM** | | | | | 07:00 Balcony Room 1
Meet the Professor 1
Vitamin D – how much is enough?, Paul Lips
07:00 Balcony Room 1
Meet the Professor 2
Of mice and men: animal models for human diseases, Ralph Müller
07:00 Balcony Room 2
Meet the Professor 3
HIV and bone, Juliet Compton
07:00 Rotunda at Elder Park, Adelaide Fun Run
--- | | | | | 08:30 Balcony Rooms 1/2
ADVANCED QUANTITATIVE BONE IMAGING: BEYOND DXA
08:30 Balloon Room B/C
Session 1
Basic bone anabolism
Chairs: Natalie Sims & Paul Baldock
M Kneissel
H Zhou
G Duque
G Thomas
08:30 Balloon Room B/C
Session 5
Novel therapeutic approaches for osteoporosis management
Chairs: Emma Duncan & Peter Ebeling
M Kneissel
J Martin
J Compton
M Rybchyn
08:30 Balloon Room B/C
Session 9
The bone/joint interface
Chairs: Malcolm Smith & Gethin Thomas
J Kuliwaba
N Walsh
G Jones
R Gu
I Poulton
--- | | | | | 10:20 – 10:50 AQB WORKSHOP REFRESHMENTS
Exhibition Foyer
10:10 – 10:40 REFRESHMENTS
Exhibition Foyer
10:16 – 10:40 REFRESHMENTS
Exhibition Foyer
10:10 – 10:30 REFRESHMENTS
Exhibition Foyer
--- | | | | | 10:50 Balcony Rooms 1/2
ADVANCED QUANTITATIVE BONE IMAGING: BEYOND DXA continues...
10:40 Balloon Room B/C
Session 2
Novel insights into osteoporosis pathophysiology
Chairs: John Esman & Rob Daly
R Müller
J Compton
M Brown
IPL Wong
10:30 Balloon Room B/C
Session 6
Quantifying bone quality
Session supported by Servier Laboratories (Aust) Pty Ltd
Chairs: Mark Forwood & Roger Price
R Müller
R Zebaze
C Langton
E Penlisi
MY Chan
10:30 Balloon Room B/C
Session 10
Vitamin D
Chairs: Rory Clifton-Bligh & Paul Anderson
H Morris
P Lips
M Boltland
K Sanders
J Rampellini
--- | | | | | 12:20 – 13:00 AQB WORKSHOP LUNCH
Exhibition Foyer
12:00 – 16:30 Suite 4 ANZBMS Council Meeting
12:30 – 14:00 LUNCH & Trade Exhibition
Poster Session - odds
13:00 – 14:00 Ballroom B/C
INDUSTRY SYMPOSIUM
AMGEN/GSK SYMPOSIUM
The impact of denosumab inhibition: from microarchitecture to outcomes
Chair: Prof Philip Sambrook
The prevention of structural decay using RANK Ligand inhibition
Prof Ego Serman
Clinical aspects of denosumab
Prof Juliet Compton
12:30 – 14:00 LUNCH & Trade Exhibition
Poster Session - evens
13:00 – 14:00 Ballroom B/C
INDUSTRY SYMPOSIUM
SERVIER LABORATORIES SYMPOSIUM
Cortical bone and fracture risk
Chair: Prof Philip Sambrook
Strontium ranelate and bone: moving beyond the DXA mindset
Prof Greame Jones
Title to be confirmed
A/Prof Mark Kotowicz
12:45 – 14:00 LUNCH
Brasserie Restaurant, Ground Floor
--- | | | | | 13:50-14:30 Balcony Rooms 1/2
ADVANCED QUANTITATIVE BONE IMAGING: BEYOND DXA continues...
14:00 Balloon Room B/C
Session 3
Osteoimmunology – classical and modern aspects
Session supported by Amgen in collaboration with GSK
Chairs: Matt Gillespie & Louise Purdon
G Atkins
K Alexander
J-P Levesque
J Xu
14:00 Balloon Room B/C
Session 7
Young Investigator Awards
Chairs: Jill Cornish & Jackie Center
14:00 Balloon Room B/C
Session 11
Novel insights into osteoporosis pathophysiology
Chairs: John Esman & Rob Daly
R Müller
J Compton
M Brown
IPL Wong
--- | | | | | 14:30 – 15:00 BONES TO BENCH WORKSHOP REFRESHMENTS
Royal Adelaide Hospital
14:30 – 16:05 REFRESHMENTS
Exhibition Foyer
14:40 – 16:00 REFRESHMENTS
Exhibition Foyer
--- | | | | | 15:00 – 16:30 Royal Adelaide Hospital FROM BONES TO BENCH AND BACK AGAIN: THE SCIENCE UNDERLYING OUR CLINICAL REASONING AND THE CLINICAL RELEVANCE OF RESEARCH continues...
15:00 – 16:30 Royal Adelaide Hospital FROM BONES TO BENCH AND BACK AGAIN: THE SCIENCE UNDERLYING OUR CLINICAL REASONING AND THE CLINICAL RELEVANCE OF RESEARCH continues...
16:05 PARALLEL ORAL SESSIONS
Free Oral Communications
Session 4A Clinical
Balloon B
Including Outstanding Clinical Abstract
Session 4B Basic Balloon C
Including Outstanding Basic Abstract
17:20 Sessions Close
16:00 Balloon Room B/C
Session 8
Greg Mundy Memorial Lecture
Chair: Colin Dunstan
Jack Martin
17:00 ANZBMS AGM
--- | | | | | 17:00 WELCOME RECEPTION
Exhibition Foyer, Mezzanine Level, Hilton Adelaide
18:30 YOUNG SCIENTISTS AND STUDENTS’ DINNER
T Chow Restaurant, Gouger Street
18:30 – 19:00 ANZBMS WOMEN’S EVENT
19:00 for 19:30 – 23:30
CONFERENCE DINNER
Hilton Adelaide Ballroom
### ADVANCED QUANTITATIVE BONE IMAGING: BEYOND DXA

**Chair:** Ian Reid

- **08:30** | **WORKSHOP**
  - Balcony Rooms 1 & 2, Hilton Adelaide
  - **Introduction – ANZBMS Clinical Bone Densitometry Committee**
  - **08:35**
  - **Official opening & topic overview – where have we come from and where we are going?**
    - **Richard L Prince**
  - **08:50**
  - **Recent developments in micro-CT and their applications**
    - **Ralph Müller**
  - **09:35**
  - **Title to be confirmed**
    - **Roger Zebaze**

- **10:20 – 10:50** | **Morning tea**

- **10:50**
  - **Laboratory-based micro-CT imaging studies: towards the clinic**
    - **Ian Parkinson**

- **11:35**
  - **QUS assessment of bone: time for a new paradigm?**
    - **Christian M Langton**

- **12:20 – 13:00** | **Lunch**

- **13:00**
  - **Navigating around animal ethics in research: a survivor’s guide**
    - **Timothy Kuchel**

- **13:45**
  - **Advanced imaging on the Imaging & Medical Beam Line at the Australian Synchotron: to infinity and beyond**
    - **Damian E Myers**

- **14:30** | **Meeting closure**

### FROM BONES TO BENCH AND BACK AGAIN: THE SCIENCE UNDERLYING OUR CLINICAL REASONING AND THE CLINICAL RELEVANCE OF RESEARCH

**Chair:** Ian Reid

- **13:00** | **WORKSHOP**
  - Rooms 250 & 251 in the Eleanor Harold Bldg
    - Royal Adelaide Hospital
  - **FROM BONES TO BENCH AND BACK AGAIN: THE SCIENCE UNDERLYING OUR CLINICAL REASONING AND THE CLINICAL RELEVANCE OF RESEARCH**

- **a) Grand Rounds 1 – a common clinical scenario**
- **b) Discussion groups:**
  - a. Osteoblasts/anabolics
  - b. Osteoclasts/antiresorptives
  - c. Bone quality/bone turnover markers/bone density
  - d. Genetics and OP epidemiology
- **c) Grand Rounds 2 – a more unusual clinical scenario**
- **d) Final questions and Discussion**

- **14:30 – 15:00** | **Refreshment Break**

- **15:00 – 16:30** | **Workshop continues (see above)**
  - **Royal Adelaide Hospital**

- **16:00** |
  - **Registration opens**
    - Mezzanine Level, Hilton Adelaide

- **17:00 – 19:00** |
  - **Welcome Cocktail Party, Exhibition and Poster Session (non attended)**
    - Mezzanine/Ballroom A
### Monday 6 September 2010

**Balcony Room 1**

**07:00**

**Breakfast Session**

**Meet the Professor 1**

Chair: Richard Prince

*Vitamin D – How much is enough?*

Paul Lips

---

**08:30**

**Session 1**

**Basic Bone Anabolism**

Chair: Natalie Sims and Paul Baldock

**08:30** IS1

Novel Insights on Wnt signalling in bone

Kreissel M (Switzerland)

**09:10** IS2

Osteoblasts, Wnt signalling and the effects of glucocorticoids

Zhou H and Seibel M (Australia)

**09:34** IS3

Osteoporosis in older persons: senescence vs. disease

Dugue G (Australia)

**09:58** OR1

SOST and DKK-1 are downregulated in the spines and joints of mice suffering ankylosing spondylitis creating a permissive environment for excessive bone formation

Duan R, Glant TT, Brown MA and Thomas GP

---

**10:10**

**Refreshment Break**

**Mezzanine**

---

**10:40**

**Session 2**

**Novel Insights into Osteoporosis Pathophysiology**

Chairs: John Eisman and Rob Daly

**10:40** IS4

Osteocytes – the hunt for the mechanostat

Müller R (Switzerland)

**11:10** IS5

Obesity and fractures

Compston J (United Kingdom)

**11:40** IS6

Genetic studies in osteoporosis

Brown MA (Australia)

**12:10** OR2

Modulation of PYY regulates bone formation – a signal from gut to bone?

Wong IPL, Shi YC, Enriquez RF, Sainsbury A, Herzog H, Eisman JA and Baldock PA

---

**12:30** - 14:00

**Lunch and poster sessions**

**Mezzanine**

Poster Numbers presenting: Odds

---

**13:00** - 14:00

**AMGEN/Gsk Symposium**

Supported by Amgen in collaboration with GSK

*The Impact of Denosumab Inhibition from Microarchitecture to Outcomes*

Chair: Prof Philip Sambrook

The prevention of structural decay using RANK Ligand inhibition

Prof Ego Seeman

Clinical aspects of denosumab

Prof Juliet Compston
MONDAY 6 SEPTEMBER 2010 CONT...

14:00  SESSION 3
Osteoimmunology – classical and modern aspects
Session supported by Amgen in collaboration with GSK
Chairs: Matt Gillespie and Louise Purton

14:00  IS7  Inflammatory mediators: triggers of the bone anabolic-catabolic switch
Atkins G (Australia)

14:24  IS8  Osteomacs versus inflammatory macrophages in bone biology
Raggatt L (Australia)

14:48  IS9  Unraveling the endosteal hematopoietic stem cell niche - induction of mobilization
Levesque J-P (Australia)

15:18  IS10  RANKL and its signaling as therapeutic targets for osteolytic bone diseases
Xu J (Australia)

15:45 – 16:05  Refreshments and poster session  Mezzanine

16:05 – 17:20  PARALLEL ORAL PRESENTATIONS

16:05  SESSION 4A
Clinical Presentations
Chairs: Tania Winzenburg and John Wark

16:05  OR3  Outstanding Abstract – Clinical
A dedicated intervention program reduces refracture rates in patients with incident non-vertebral osteoporotic fracture: Results of a 4-year prospective controlled study (OMEN)
Lih A, Nandapalan H, Kim M and Seibel MJ

16:17  OR4  Calcium supplementation and the risks of atherosclerotic vascular disease in postmenopausal women
Lewis JR, Calver J, Zhu K, Flicker L and Prince RL

16:29  OR5  Depletion of osteoclastic-like giant cells by denosumab alters the differentiation of stromal-like tumour cells in giant cell tumour of bone


16:53  OR7  Evidence of Gene-Gene Interaction Determinants of Fracture Susceptibility
Tran BNH, Nguyen ND, Center JR, Eisman JA and Nguyen TV

17:05  OR8  Frequent walking is associated with an increased fracture risk in middle aged and older adults: A national, population-based prospective study (AusDiab)
Nikander R, Gagnon C, Dunstan DW, Ebeling PR, Magliano DJ, Zimmet P, Shaw J and Daly RM
16:05      SESSION 4B  
**Basic Presentations**  
*Chairs: Rebecca Mason and David Findlay*  

16:05 OR9 **Outstanding Abstract – Basic**  
Enhanced osteoclast formation in Oncostatin M receptor knockout (OSMR KO) mice in response to Parathyroid Hormone (PTH)  
Walker EC, McGregor NE, Poulton IJ, Ho P, Allan EA, Martin TJ and Sims NA  

16:17 OR10 Trabecular bone volume is increased in a novel mouse model expressing an osteoblast-specific CYP27B1 transgene  
Turner AG, Tyson JHT, Sawyer RK, O’Loughlin PD, Atkins GJ, Kogawa M, Findlay DM, Morris HA and Anderson PH  

16:29 OR11 Neuropeptide Y, Y6 receptor (Y6R) - a novel regulator of bone mass and energy homeostasis  
Driessler F, Yulyaningsih E, Enriques RF, Sainsbury A, Herzog H, Eisman JA and Baldock PA  

16:41 OR12 Homozygous deletion of the Sost gene results in enhanced healing and increased callus formation in healing fractures  
McDonald MM, Morse A, Peacock L, Mikulec K, Kramer I, Kneissel M and Little DG  

16:53 OR13 The antipsychotic clozapine, but not its derivative quetiapine, induces microarchitectural changes in bone  

17:05 OR14 Skeletal cell apoptosis in methotrexate cancer chemotherapy-induced bone loss  
Fan CM, Ng YS, Shandala T, Georgiou KR, King T, Scherer MA, Cool JC, Yip YC, Hopwood B, Foster BK and Xian CJ  

17:20  Sessions Close  

18:30  Young Scientists and Students’ Dinner  
*T-Chow Chinese Restaurant*  

19:00  President’s Dinner  
*Bistro Dom*
### TUESDAY 7 SEPTEMBER 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 07:00  | BREAKFAST SESSION | MEET THE PROFESSOR 2 | Chair: Liza Raggatt  
Of mice and men: animal models for human diseases  
Ralph Müller  
Balcony Room 1 |
|        |         | MEET THE PROFESSOR 3 | Chair: Bronwyn Crawford  
HIV and bone  
Juliet Compston  
Balcony Room 2 |
| 08:30  | SESSION 5 | Novel therapeutic approaches for osteoporosis management | Chair: Emma Duncan and Peter Ebeling  
Ballroom B/C |
| 08:30  | IS11    | Sclerostin: therapeutic potential of targeting SOST action in bone | Kneissel M (Switzerland) |
| 09:00  | IS12    | Could ephrins be therapeutic targets in osteoporosis? | Martin J (Australia) |
| 09:24  | IS13    | Osteoporosis: Increased resorption or failed anabolism: New approaches to therapeutic management | Compston J (UK) |
| 10:04  | OR15    | Strontium ranelate-induced osteogenic effects in human osteoblasts via a sclerostin decrease and a canonical Wnt signaling increase | Rybchyn MS, Conigrave AD and Mason RS |
| 10:16  |        | Refreshment Break | Mezzanine |
| 10:40  | SESSION 6 | Quantifying bone quality | Session supported by Servier Laboratories (Aust) Pty Ltd  
Chair: Mark Forwood and Roger Price  
Ballroom B/C |
| 10:40  | IS14    | Bone imaging - the future | Müller R (Switzerland) |
| 11:20  | IS15    | Cortical bone decay: beyond density and thickness | Zebaze R (Australia) |
| 11:44  | IS16    | Clinical bone imaging: beyond BMD... | Langton CM (Australia) |
| 12:08  | OR16    | Bone mineral density assessed via DXA and microarchitecture assessed via micro-CT: predicting whole vertebral body strength | Perilli E, Briggs AM, Codrington JD, Wark JD, Kantor S, Parkinson IH and Fazzalari NL |
| 12:20  | OR17    | Prognosis of fracture risk by quantitative-ultrasound measurement and bone mineral density | Chan MY, Nguyen DN, Center JR, Eisman JA and Nguyen TV |
12:32 – 14:00 Lunch and poster sessions
Poster Numbers presenting: Evens

13:00 – 14:00 SERVIER SYMPOSIUM
Cortical bone and fracture risk
Chair: Prof Philip Sambrook
Strontium ranelate and bone: moving beyond the DXA mindset
Prof Graeme Jones
Title to be confirmed
A/Prof Mark Kotowicz

14:00 SESSION 7
Young Investigator Awards
Chairs: Jill Cornish and Jackie Center

14:00 OR18 Atypical femoral fractures are associated with bisphosphonate use
Girgis CM, Sher D and Seibel MJ

14:12 OR19 Treatment with interleukin-6 receptor antibodies inhibits breast cancer growth in a murine model of bone metastasis

14:24 OR20 Micro-CT and biomechanical analysis of the leptin receptor-deficient db/db mouse tibia

14:36 OR21 Calcium supplementation does not rescue the programmed adult bone deficits associated with perinatal growth restriction
Romano T, Wark JD and Wlodek ME

14:48 OR22 Comparison of the FRISK Score to the FRAX (UK) Algorithm and Garvan Nomogram:
Geelong Osteoporosis Study
Zhang Y, Pasco JA, Kotowicz MA, Sanders KM, Nicholson GC and Henry MJ

15:00 OR23 Choline Kinase Beta is a critical regulator of bone homeostasis
Kular J, Tickner J, Davey T, Lim B, Qian Y, Ang E, Zheng MH and Xu J

15:12 OR24 The association between oral contraceptive use, bone mass and fractures in both young and older women
Wei S, Venn A and Jones G

15:24 OR25 Apomab, a fully human agonistic DR5 monoclonal antibody, inhibits tumour growth and osteolysis in murine models of breast cancer development and progression

15:40 – 16:00 Refreshments

16:00 SESSION 8
Greg Mundy Memorial Lecture
Chairs: Colin Dunstan
Jack Martin

17:00 ANZBMS AGM
Sessions Close

18:30 ‘Women In Bone’ Networking Event

19:00 for 19:30 – 11:30 Conference Dinner
### 20th Annual Scientific Meeting of the Australian & New Zealand Bone & Mineral Society

**WEDNESDAY 8 SEPTEMBER 2010**

**07:00**  
FUN RUN  
Rotunda in Elder Park, Adelaide

**08:30**  
**SESSION 9**  
The bone/joint interface  
Chair: Malcolm Smith and Gethin Thomas

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
</table>
| 08:30 | IS17 Basic aspects of OA  
Kuliwaba JS and Fazzalari NL (Australia) | Ballroom B/C |
| 08:54 | IS18 Bone remodelling in inflammatory arthritis  
Walsh N (Australia) | |
| 09:18 | IS19 Clinical aspects of OA  
Jones G (Australia) | |
| 09:42 | OR26 Macrophage migration inhibitory factor (MIF) promotes osteoclastogenesis and arthritic bone erosion  
Gu R, Santos LL, Xu J, Quinn JMW, Gillespie MT and Morand EF | |
| 09:54 | OR27 Leukemia Inhibitory Factor inhibits resorption of mineralised cartilage during growth and stimulates bone formation in remodelling  
Poulton IJ, McGregor NE, Walker EC, Pompolo S, Martin TJ and Sims NA | |

**10:10 – 10:30**  
Refreshment Break  
Mezzanine

**10:30**  
**SESSION 10**  
Vitamin D  
Chair: Rory Clifton-Bligh and Paul Anderson

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
</table>
| 10:30 | IS20 Basic aspects of vitamin D  
Morris H (Australia) | Ballroom B/C |
| 10:55 | IS21 Vitamin D: canonical and non-canonical  
Lips P (The Netherlands) | |
| 11:35 | IS22 Vitamin D supplements do not mitigate the effect of calcium supplements on cardiovascular events  
Bolland M (New Zealand) | |
| 11:59 | IS23 Changes in muscle strength three-months after annual 500,000 IU dose of cholecalciferol: Further analysis from the Vital D Study  
Sanders K (Australia) | |
| 12:23 | OR28 The effects of a nine month RCT of vitamin D supplementation (150,000 IU every 3 months) on bone density and muscle strength in older postmenopausal women  
| 12:35 |  
*It is anticipated that there will be extended discussion after this session led by chairs.* | |

**12:45**  
Lunch and Conclusion  
Brasserie Restaurant, Ground Floor
# POSTER PRESENTATIONS

## Malignant bone disease

<table>
<thead>
<tr>
<th>P1</th>
<th>Vitamin D deficiency promotes human prostate cancer growth in a murine model of bone metastasis</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P2</th>
<th>The role of tumour derived interleukin 6 in a murine model of breast cancer bone metastasis</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P3</th>
<th>Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo</th>
</tr>
</thead>
</table>

## Orthopaedics

<table>
<thead>
<tr>
<th>P4</th>
<th>Muscle progenitors make a major contribution to open fracture repair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schindeler A, Liu R, Peacock L, Mikulec K, Morse A and Little DG</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P5</th>
<th>A comparison of lumbar intervertebral disc height in mature and adolescent sheep following injection of a matrix degrading enzyme</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decelis M, Moore RJ and Vernon-Roberts B</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P6</th>
<th>Inhibition of osteoclastogenesis in patients with traumatic brain injury: a possible contributor towards increased callus size and enhanced fracture healing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Mushaigri MS and Filgueira L</td>
<td></td>
</tr>
</tbody>
</table>

## Clinical metabolic bone diseases

<table>
<thead>
<tr>
<th>P9</th>
<th>Hypophosphataemic osteomalacia in two patients on adefovir dipivoxil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Girgis CM, Wong T, Ngu M, Emmett L, Archer K, Chen RC and Seibel MJ</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P10</th>
<th>Proteomic assessment of cell surface proteins of periodontal cell subsets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xiong J, Gronthos S, Zilm P and Bartold M</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P11</th>
<th>The first case report of hypophosphataemic osteomalacia secondary to deferasirox therapy and clinical audit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mist E, Johnstone L, Kerr PG, Doery JCG, Strauss BJ and Bowden DK</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P12</th>
<th>Can craniosynostosis give a leg up to fighting other bone diseases?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hatfield J, Hinze SJ, Anderson P and Powell BC</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P13</th>
<th>Higher expression of ITAM-related osteoclastogenesis co-stimulatory factors in is associated with peri-implant osteolysis tissues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alias E, Dharmapati ASSK, Nealen SD, Crotti TN and Haynes DR</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P14</th>
<th>Bone cell abnormalities in vitro from a patient with a rare bone condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barron ML, Clifton-Bligh R, Clifton-Bligh P, Bonar F, Stalley PD and Mason RS</td>
<td></td>
</tr>
</tbody>
</table>

## Clinical - other

<table>
<thead>
<tr>
<th>P15</th>
<th>Longitudinal studies of bone health during antiepileptic drug (AED) therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shiek Ahmad B, Wark JD, Hill K, O’Brien TJ, Petty SJ and Kantor S</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P16</th>
<th>Dietary Emu Oil supplementation may suppress chemotherapy-induced formation of bone-resorptive cells osteoclasts and prevent bone loss</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P17</th>
<th>Errors in self reported myocardial infarction in calcium intervention studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lewis JR, Zhu K and Prince RL</td>
<td></td>
</tr>
</tbody>
</table>
# POSTER PRESENTATIONS

### Public health

| P19 | Persistence to oral osteoporosis therapy in Australia Maclean A and Calcino G |
| P20 | Geographical variation in bone density in South Australia Wormald JL and Schultz CG |
| P21 | Socioeconomic status and bone health in older men: The CHAMP study Nabipour I, Cumming RG, Handelsman DJ, Naganathan V, Waite L, Janu M, Le Couteur D, Sambrook PN and Seibel MJ |
| P22 | A cultural models approach to osteoporosis prevention and treatment Otmar R, Morrow M, Nicholson GC, Kotowicz MA and Pasco JA |
| P23 | The utility of bone health to predict mortality in older women Gould H, Pasco JA, Brennan SL, Kotowicz MA, Nicholson GC and Henry MJ |
| P24 | Development of a Model of Care for osteoporosis in Western Australia utilising Health Networks Briffa NK, Briggs AM and France L |

### Epidemiology and genetics

| P28 | Clinical utility of combined femoral neck and lumbar spine bone mineral density measurements in the individualized prognosis of fracture Nguyen TV, Nguyen ND, Frost SA, Bluc D, Center JR and Eisman JA |
| P29 | Relationship between low BMD and fracture in mortality risk: an 18-year prospective study from Dubbo Osteoporosis Epidemiology Study Bluc D, Nguyen ND, Nguyen TV, Eisman JA and Center JR |
| P30 | Osteoporosis medication and reduced mortality risk in elderly women and men: an 18-year prospective study from the Dubbo Osteoporosis Epidemiology Study Center JR, Bluc D, Nguyen ND, Nguyen TV and Eisman JA |
| P31 | Determinants of bone mass in smokers: A study in smoking-discordant twin pairs Christie JJ, Osborne RH, Kantor S, Nowson CA, Seibel MJ, Sambrook PN and Wark JD |
| P32 | Table tennis activity is positively associated with bone mineral measures in older Asian Australian women and men Li L, Apandi A and Wark JD |
| P33 | Pleiotropic genetic effects contribute to the correlation between bone mineral density and quantitative ultrasound measurements Nguyen SC, Nguyen ND, Center JR, Eisman JA and Nguyen TV |
| P34 | BMD in a cohort of women a decade apart: Geelong Osteoporosis Study Henry MJ, Kotowicz MA, Nicholson GC, Clark E and Pasco JA |
POSTER PRESENTATIONS

P36 Association between beta-blocker use and bone loss: the Dubbo Osteoporosis Epidemiology Study
Yang S, Nguyen ND, Center JR, Eisman JA and Nguyen TV

P37 Relationship between dietary selenium intake and bone mineral density across multiple anatomical sites in adult women

P38 Effects of vitamin D deficiency and high parathyroid hormone on mortality risk in elderly men
Nguyen ND, Bluc D, Frost SA, Center JR, Eisman JA and Nguyen TV

P39 Explaining the missing heritability of osteoporosis: contributions of ESR1 and LRP4 polymorphisms to fracture susceptibility in families
Tran BNH, Nguyen S, Nguyen ND, Center JR, Eisman JA and Nguyen TV

P40 Contribution of Genetic Profiling to Individualized Prognosis of Fracture
Tran BNH, Nguyen ND, Vinh NX, Center JR, Eisman JA and Nguyen TV

P41 Low-trauma fractures signal increased risk of hip fracture in frail older people
Sambrook PN, Chen JS, Cameron ID, Cumming RG, March LM and Seibel MJ

Clinical osteoporosis

P42 Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risendronate

P43 Intravenous zoledronate use in adult delayed non-union fracture healing
Gilchrist N, McKie J and Little D

P44 Zoledronic acid improves Health-related quality of life in patients with hip fracture: Results of HORIZON-RFT

P45 Subtrochanteric fractures: results from the HORIZON-Recurrent Fracture Trial

P46 Measures of body fat are associated with prevalent vertebral deformities in older women but not men
Laslett LL, Just S, Quinn S, Winzenberg TM, and Jones G

P47 Zoledronic acid (ZOL) prevents bone loss in postmenopausal women with low bone mineral density (BMD): The HORIZON prevention study

P48 Effect of Denosumab on the incidence of hip, new vertebral, and nonvertebral fractures over 3 years among postmenopausal women with higher fracture risk: a subgroup analysis from the FREEDOM Study

P49 Characterization of and risk factors for acute phase reactions following zoledronic acid infusion
Reid IR, Gamble GD, Mesenbrink P and Black DM

P50 Dairy Phospholipid for Bone Health
Watson M, Guan J, Callon KE, MacGibbon AKH, Reid IR, McJarrow P and Cornish J

P51 Low treatment rates of vertebral fractures in a large New Zealand District Health Board
Singh J and Bloomfield K

P52 Audit of bone protection treatment in patients aged 65 yrs presenting to North Shore Hospital with fractures
Singh J

P53 Paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion of zoledronic acid
Wark JD, Bensen W, Recknor C, Ryabtseva O, Chiodo III J, Mesenbrink P and De Villiers TJ
P54 The effects of a two year RCT of whey protein supplementation on bone density and urinary calcium excretion in older postmenopausal women
Zhu K, Meng X, Kerr DA, Devine A, Solah V, Binns CW and Prince RL

P55 Identification of osteoporosis through a retrospective and prospective audit in patients following an acute fracture
Heard A, Anderson L, Maguire P, Gilchrist N and McKie J

P56 Zoledronic acid reduces the increased risk conferred by further fractures
Seeman E, Black DM, Bucci-Rechtweg C, Eastell R, Boonen S and Mesenbrink P

Bone quality, bone structure and mechanical properties

P57 Relationship between baseline remodelling intensity and changes in HR-pQCT parameters at the radius in postmenopausal women treated with denosumab or alendronate

P59 Reduced osteocyte density and morphological changes of canaliculi in trabecular bone of osteoporotic sheep
Zarrinkalam MR, Mulaibrahimovic A, Nguyen AQ, Sarvestani GT, Vernon-Roberts and Moore RJ

P60 Osteoporotic characteristics in vertebral trabecular bone of osteoporotic sheep remain after withdrawal of corticosteroid administration
Zarrinkalam MR, Schultz C, Parkinson I and Moore RJ

P61 In vivo imaging of subchondral bone using micro-CT in a rodent model of osteoarthritis
Mohan G, Perilli E, Kuliwaba JS, Humphries JM, Parkinson IH and Fazzalari NL

P62 Fatty acid composition of osteoarthritic, osteoporotic and control femoral heads
Humphries JM, Gibson RJ and Fazzalari NL

P63 Peri-osteocytic osteolysis with no decline in osteocyte-lacunae density occurs in association with bone volume loss due to estrogen depletion
Anderson PH, Sawyer RK and Atkins GJ

P65 Measurement of ex vivo subregional vertebral bone mineral density using lateral projection dual energy X-ray absorptiometry (DXA): validation with peripheral quantitative computed tomography (pQCT)
Briggs AM, Perilli E, Parkinson IH, Wrigley T, Fazzalari NL, Kantor S and Wark JD

P66 Regional analysis of trabecular bone microdamage in the human lumbar vertebra
Tsangari H, Kuliwaba JS, Badiei A and Fazzalari NL

P67 Increased density of hypermineralised osteocyte lacunae and microdamage accumulation in fragility hip fracture patients

P68 Combined high dietary calcium and vitamin D are necessary to improve cortical thickness to resist bone failure in senescent animals
Lee AMC, Anderson PH, Sawyer RH, Moore AJ, Morris HA and O’Loughlin PD

P69 BMD, trabecular architecture and bone turnover following estrogen deficiency in an ovine model of osteoporosis
Brennan O, Kuliwaba JS, Kennedy OD, Lee TC, Parkinson IH, Fazzalari NL, McNamara LM and O’Brien FJ

P70 Historically active postmenopausal women have greater trabecular bone volume and thickness than inactive women
Ganovick J, Bailey C, Ebeling PR, Krug R, Majumdar S and Daly RM

P71 Quantifying intracortical porosity producing cortical remnants identifies individuals at risk for fracture beyond existing parameters
Zebaze R, Ghasem-Zadeh A, Iuliano-Burns S, King K and Seeman E
POSTER PRESENTATIONS

P72 Defining a region’s surface/volume ratio identifies its susceptibility to being remodelled and decayed better than bone density measurements
Ghasem-Zadeh A, Zebaze R, Iuliano-Burns S, King K and Seeman E

P73 Creation of a 3D finite element analysis model of the proximal femur incorporating cortical, trabecular and medullary compartments derived from a single 2D DXA scan image
Baker AM and Langton CM

P74 A new approach to modelling bone remodelling: Smooth Particle Hydrodynamics
Thomas CDL, Fernandez JW, Das R, Cleary PW and Clement JG

P75 Synchrotron-radiation micro-ct of cortical bone reveals new data on osteocyte lacunar volume and spacing
Thomas CDL, Hannah KM, Peele AG, DeCarlo F and Clement JG

P76 Are changes in muscle size related to changes in bone material and structural properties at the axial and appendicular skeleton in older men? An 18-month study.
Baley CA, Kukuljan S and Daly RM

P77 Effect of fatigue-induced microdamage on the fracture resistance of human cortical bone
Codrington JD, Fazzalari NL and Kotousov AG

P78 Metaphyseal trabecular architecture is established and decayed early in life

Cell biology

P79 Functional involvement of the microtubule-binding dynein-dynactin complex in osteoclast formation and bone resorption
Ng PY, Cheng T, Feng HT, Ang E, Zheng MH, Xu J, Zhao H and Pavlos NJ

P80 Ac45 mediates acidification and endocytosis during osteoclast bone resorption
Qin A, Cheng TS, Pavlos NJ, Xu J, Dai K and Zheng MH

P81 The effects of arachidonic acid and docosahexaenoic acid on proliferation of and osteoclast formation from RAW 264.7 murine monocytes
Coetzeee M, Boyens JCA, Stander BA, Fray LM, Hiess JR, Chua WH and Kruger MC

P82 Grape seed proanthocyanidin extract inhibits osteoclast differentiation and resorption while having no effect on osteoblast proliferation in vivo
Chua WH, Pimlin GG, Hiess J, and Kruger MC

P83 Culture of non-bone cells on bisphosphonate-coated bovine bone - an in vitro model of osteonecrosis of the jaw (ONJ)
Bava U, Cornish J and Reid IR

P84 Osteoblast growth and differentiation in two- and three-dimensional cultures
Matthews BG, Calon KE, Locklin RM, Hulley PA, Naot D and Cornish J

P85 Calcium promotes osteoblast differentiation resulting in an enhanced osteocyte-like phenotype in mineralised cultures of human primary osteoblasts
Welldon KJ, Findlay DM and Atkins GJ

P86 EphB/ephrin-B interactions mediate MSC recruitment and differentiation: potential implications in bone remodelling
Arthur A, Borowicz R, Zanettino ACW, Sims NA, Matsuo K and Gronthos S

P87 Both class I and class II histone deacetylases (HDACs) are important during osteoclast development
Cantley MD, Fairlie DP, Bartold PM, Lucke A and Haynes DR

P88 Role of neuropeptide Y1 receptor signalling blockade on osteoblast activity
Sousa DM, Neto EC, Estêvão MI and Lamghari M

P89 17-allylamino geldanamycin (17AAG) increases osteoclast formation in vitro through the induction of a cell stress response
Quinn JMW, Chai R, Koustrup MM, Xu J, Gillespie MT and Price JT
### POSTER PRESENTATIONS

| P90  | Critical molecular regulators, histomorphometric indices and their correlations in the trabecular bone in primary hip osteoarthritis  
  | Kumarasinghe DD, Perilli E, Tsangari H, Truong L, Kuliwaba JS, Hopwood B, Atkins GJ and Fazzalari NL |
| P91  | The TWIST family of basic-helix-loop-helix transcription factors, Twist-1 and-2, mediate mesenchymal stromal/stem cell proliferation and differentiation  
  | Cooper L, Isenmann S, Arthur A, Zannettino A, Cakouros D, Glackin C and Gronthos S |
| P92  | Differential gene expression in osteochondrosis lesions  
  | Mirams M, Pagel CN and Mackie EJ |
| P93  | JNK inhibitors promote osteogenic differentiation in NF1-deficient cells  
  | Sullivan K, Schindeler A and Little DG |
| P94  | Localisation of RBP4 in human suture derived cells from craniosynostosis patients suggests a site specific function  
  | Leitch VD, Hinze SJ, Anderson PJ and Powell BC |
| P95  | Microtubule motor protein Tctex-1 interacts with Rab3D and is required for osteoclastic bone resorption  
  | Pavlos NJ, Cheng TS, Qin A, Feng HT, Ng PY, Ang ESM, Carrello A, Sung CH, Jahn R, Zheng MH and Xu J |
| P96  | Mechanisms of erosive gout: monosodium urate monohydrate crystals inhibit osteoblast viability and function  
  | Chhana A, Callon KE, Pool B, Naot D, Watson M, Comish J and Dalbeth N |

#### Basic - other

| P97  | Mangiferin attenuates osteoclastogenesis, bone resorption and RANKL-induced activation of NF-kB and ERK  
  | Ang E, Liu Q, Qi M, Liu HG, Zheng MH and Xu J |
| P98  | Homozgyous deletion of Dickkopf-1 results in a high bone mass phenotype  
  | McDonald MM, Morse A, Baldock PA, Peacock L, Khoo P-L, Tam PPL and Little DG |
| P99  | The impact of pregnancy and lactation on bone in rat mothers exposed to uteroplacental insufficiency  
  | Romano T, Wark JD and Wlodek ME |
| P100 | The angiotensin converting enzyme inhibitor, captopril, reduces bone quality in ovary-intact rats but not in ovarioectomized rats  
  | Blazeska M, Chan V, Jois M, McDonald AC, Ward AR, Schuijers JA and Grills BL |
| P101 | Endothelin-1 receptor and myofibroblast-like cells in early soft callus: a potential role in fracture healing  
  | McDonald SJ, Dooley PC, McDonald AC, Schuijers JA, Ward AR and Grills BL |

#### Mineral regulating hormones (including vitamin D)

| P102 | Increased bone VDR impairs osteoclast and osteoblast activities with low dietary calcium in a mouse model  
  | Lam NN, O’Loughlin PD, Sawyer RK, Morris HA and Anderson PH |
| P103 | Glutathione analogs are potent suppressors of PTH secretion from human parathyroid cells  
  | Mun H-C, Broadhead GK, Avlani VA, Jourdon O, Christopoulos A, Church WB, Delbridge L and Conigrave AD |
| P104 | Volume resuscitation confounds the interpretation of serum vitamin D concentrations in critically ill patients  
  | Ochola J, Krishnan A, Kruger P, Mundy J, Jones M, Duncan EI and Venkatesh B |
| P105 | Vitamin D and bone mineral metabolism in obese patients prior to laparoscopic adjustable gastric banding  
  | Yong TY and Li JYZ |
| P106 | Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption  
  | Kogawa M |
## POSTER PRESENTATIONS

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P107</td>
<td>The role of vitamin D in the proliferation and differentiation of osteoblasts</td>
<td>Yang D, Atkins GJ, Anderson PH, Welldon KJ and Morris HA</td>
</tr>
<tr>
<td>P108</td>
<td>Vitamin D and bone health in Australian Aboriginals</td>
<td>Vanlint S, Morris H, Newbury J and Crockett A</td>
</tr>
<tr>
<td>P109</td>
<td>The effect of receptor density on the function of the extracellular calcium-sensing receptor</td>
<td>Brennan SC, Christopoulous A and Conigrave AD</td>
</tr>
<tr>
<td>P110</td>
<td>Intermittent high-dose vitamin D3 corrects vitamin D deficiency in adolescents: results from a randomised controlled trial</td>
<td>Carnes J, Quinn S, Nelson MR, Jones G and Winzenberg T</td>
</tr>
<tr>
<td>P111</td>
<td>The skeletal response to vitamin D supplementation during sunlight deprivation: a randomised trial in Antarctic expeditioners</td>
<td>Juliano-Burns S, King K, Ayton J, Hillam S, Jones G and Seeman E</td>
</tr>
<tr>
<td>P114</td>
<td>Wnt7b plays a unique and essential role in osteoblast differentiation</td>
<td>Shao X, Fong-Yee C, Lyon K, Dunstan CR, Seibel MJ and Zhou H</td>
</tr>
<tr>
<td>P115</td>
<td>Nilotinib inhibits osteoblast proliferation and differentiation, and inhibits osteoclastogenesis</td>
<td>O Sullivan S, Lim JM, Tong PC, Watson M, Callon K, Cornish J, Browett P and Grey A</td>
</tr>
<tr>
<td>P117</td>
<td>Methionine199 in the TNF-like core domain of RANKL is crucial for RANKL function</td>
<td>Cheng TS, Qin A, Pavlos NJ, Chim SM, Tan WY, Dai K, Zheng MH and Xu J</td>
</tr>
<tr>
<td>P118</td>
<td>Regulation of OPG expression in UMR-106 osteoblast cells by angiotensin II</td>
<td>MacRae KE, Thomas WG and Sernia C</td>
</tr>
<tr>
<td>P119</td>
<td>Role of glypicans in regulation of bone morphogenetic protein signaling during skull bone growth</td>
<td>Dwivedi PP, Anderson PJ and Powell BC</td>
</tr>
<tr>
<td>P120</td>
<td>Oncostatin M is a potent regulator of IL-6 and RANKL mRNA expression in synovial fibroblasts</td>
<td>Le Goff B, McGregor NM, Romas E, Sims NA and Walsh NC</td>
</tr>
</tbody>
</table>

---

**Paediatrics**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

---

**Cytokine, growth factor and hormone mechanisms of action**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P118</td>
<td>Regulation of OPG expression in UMR-106 osteoblast cells by angiotensin II</td>
<td>MacRae KE, Thomas WG and Sernia C</td>
</tr>
</tbody>
</table>

---

**Bone and mineral metabolism**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P119</td>
<td>Role of glypicans in regulation of bone morphogenetic protein signaling during skull bone growth</td>
<td>Dwivedi PP, Anderson PJ and Powell BC</td>
</tr>
</tbody>
</table>

---

**Bone and mineral metabolism**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P120</td>
<td>Oncostatin M is a potent regulator of IL-6 and RANKL mRNA expression in synovial fibroblasts</td>
<td>Le Goff B, McGregor NM, Romas E, Sims NA and Walsh NC</td>
</tr>
</tbody>
</table>

---

**Bone and mineral metabolism**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>